Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia jamanetwork.com/journals/jamao… #leusm #LL

Becoming a hematologist/oncologist has taken years of dedication, and I couldn’t have done it without the support of my family, incredible mentors, and co-fellows. Deepest gratitude to our cancer patients—your strength and trust continue to move the field forward. Penn State Health

New U.S. FDA accelerated approval: Dato-DXd for EGFR+ NSCLC after prior EGFR therapy + platinum chemo. ▫️n=114, TROPIONLung01&05 ▫️ORR: 45% ▫️DoR: 6.5 mo ⚠️ ILD, ocular AEs, stomatitis, embryo-fetal risk OncoAlert #lcsm

FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and chemotherapy. An active agent, based on TROPION-Lung01 and 05. Important toxicities include stomatitis and ocular effects. ascopost.com/news/june-2025…

Hot off the presses! #NCCN guidelines v1.2026 now online, and it’s only 2025! Lots of supportive care and treatment updates for patients with #multiplemyeloma nccn.org

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with UChicagoCancerCenter myeloma program. nature.com/articles/s4137…

Kylian Mbappé Is this true Kylian or AI 😂

Prophylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy. ow.ly/3wzs50WuY43

Prophylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy. ow.ly/x7Iw50WuYcp #clinicaltrialsandobservations #immunobiologyandimmunotherapy

Brief thread on clonal hematopoiesis #CHIP #CH #MedTwitter #hemonctrainees 1. CH assoc. with germline predisposition syndrome 2. CH assoc. with genotoxic stressors 3. CH in solid malignancies

Peripheral cell morphological alterations may signal early dysplastic shifts. In the Lifelines cohort, a high RDW links to high-risk mutational patterns in CH and stratifies the risk of death in CCUS buff.ly/Yt6TAKE @lifelinesnl UMCG

ASCO 2025 Highlights at Penn State. GI oncology updates by Dr. Yee! @PennStateHershey

RadOnc ASCO 2025 updates from Dr. Siddiqui. Zain Siddiqui Penn State Health

But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs! v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500... Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!

📊 CAR-T vs Bispecifics in R/R DLBCL (Meta-analysis, Blood 2024) •CR rate (efficacy): 🔴 CAR-T: 51% 🔵 Bispecifics: 36% 🟢 Bispecifics in CAR-T–naïve: 37% •1-year PFS: 🔴 CAR-T: 44% 🔵 Bispecifics: 32% •Grade ≥3 AEs: ⚠️ CRS: CAR-T 8% vs Bispecifics 2% ⚠️ Neurotoxicity: CAR-T

Survival after incidental vs symptomatic FL: - 908 pts, 29% incidental - incidental: more early stage & normal LDH - no diff in EFS, lymphoma-specific survival, or OS between groups We can answer the "what if this was picked up earlier" question! #lymsm nature.com/articles/s4140…

🧬 AML (unfit for intensive therapy) ➡️ Standard: Venetoclax + HMA 🔹 FLT3 → +Gilteritinib 🔹 IDH1 → +Ivosidenib 🔹 IDH2 → +Enasidenib 🔹 KMT2A → +Revumenib 🔹 TP53 → HMA ± Ven ⚠️ Cycle 1: TLS prophylaxis, azole-adjusted Ven, BMBx at day 21 #AML #Leukemia #Hematology

New in JACC HF: #Transferrin Saturation Is a Better Predictor Than Ferritin of Metabolic and Hemodynamic Exercise Responses in #HFpEF shorturl.at/pknri

📄 Splenic Irradiation for Myelofibrosis before HCT – Global Study (59 pts) 🔹 Rationale: Massive 🫛splenomegaly in MF → graft failure, poor graft function, relapse risk. 🔹 Intervention: Splenic irradiation (median 7 Gy, 5 fractions) within ~2 weeks pre-HCT. 🔹 Efficacy:

🧬 Ph-like ALL Algorithm (Diagnostic + Transplant Pathway) 🔹 Step 1: Screening •LDA for gene signatures ➡️ if no fusions = exclude •FISH → Ph+ (BCR-ABL, ETV6-RUNX1, MLL) vs Ph– 🔹 Step 2: CRLF2 testing •Ph+ or Ph– → assess CRLF2 by flow cytometry •CRLF2 overexpression: